News Category
Quantum BioPharma advances a broad strategy combining drug development, consumer wellness, and royalty partnerships to address the massive unmet need ...
PolyPeptide shareholders approved a new board and the removal of transfer restrictions, clearing a key path for Samsung Biologics' tender offer and re...
The UK's MHRA has expanded antidepressant safety warnings to cover suicide risk for all ages and persistent sexual dysfunction, prompting CCHR to dema...
Cotecna Group's acquisition of Energon Labs strengthens its global life sciences platform and expands its pharmaceutical testing capabilities in India...
Apimeds Pharmaceuticals US, Inc. announced that its subsidiary MindWave Innovations will list the NILA token on Pionex Exchange on October 14, 2026, a...
Nutriband Inc. (NASDAQ: NTRB) raised approximately $1.75 million through warrant exercises, funding the remaining clinical development and New Drug Ap...
DuLac Farmaceutici is advancing its U.S. retail strategy following productive meetings at the 2026 ECRM Vitamin, Weight Management & Sports Nutrition ...
Nutriband Inc. has filed a non-provisional utility patent application with the USPTO for improved aversive formulations and coating methods that could...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could significantly reduce animal testing, accelerate clinical advancement, and lo...
Nutriband's five-year Nasdaq listing anniversary highlights its progress in developing an abuse-deterrent fentanyl patch, a product that could address...
Helus Pharma Inc. has officially changed its legal name from Cybin Inc., effective October 1, 2026, after shareholder approval, marking its transition...
VERAXA Biotech has advanced its VXA-222 bispecific ADC program beyond discovery, planning final candidate engineering and preclinical studies, while e...
Apimeds Pharmaceuticals subsidiary MindWave Innovations will develop a blockchain for tracking digital broadcasting rights and match tickets, receivin...
Creative Biolabs integrates glycoprotein development with glycan characterization to help researchers understand how production-related variations aff...
Helus Pharma shareholders approved a legal name change from Cybin Inc. and elected directors at the annual meeting, signaling the company's shift from...
Nutriband's decision not to extend or reprice its expiring warrants could inject up to $5.86 million into the company if exercised, while warrant hold...
Peptide Wholesale Supply now applies HPLC testing and batch traceability to bulk orders of BPC-157, Semaglutide, and Tirzepatide, enhancing analytical...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma cell lines at similar low concentrations, supporti...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing ENV-105, a promising antibody des...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial signifies a pivotal step toward a novel therapy that may repair myelin damage in multiple...
Nutriband received a USPTO Notice of Publication for trademarks related to its abuse-deterrent fentanyl patch, moving closer to full trademark protect...
Quantum BioPharma receives a 'Buy' rating and $8.00 price target from Rodman & Renshaw, highlighting the potential of its lead candidate Lucid-MS for ...
Earth Science Tech's acquisition of Zoolzy LLC enhances its profit margins, expands ingredient access, and enters the veterinary market, strengthening...
Italian pharmaceutical company DuLac Farmaceutici accelerates its U.S. expansion through new e-commerce channel OneLavi and planned participation in E...
The Alliance for Safe Online Pharmacies warns that retatrutide, an unapproved investigational drug, is being illegally sold online, leading to increas...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate program moves to preclinical validation, strengthening its oncology pipeline and intellect...
Onco-Innovations' potential acquisition of an exclusive option on Ifowonco's oral LAG-3 inhibitor program could position the company at the forefront ...
Earth Science Tech's acquisition of Zoolzy is poised to enhance its compounding pharmacy margins and expand into the veterinary therapeutics market, l...
SCHOTT Pharma's parent group's updated climate targets, validated by SBTi, now include a Scope 3 absolute reduction target, shifting focus to value ch...
Helus Pharma reported completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expect...
VERAXA Biotech's VXA-222 bsADC program moves past discovery phase, and the company expands its IP portfolio with new patent filings, reinforcing its o...
Tonix Pharmaceuticals announced FDA feedback supporting its planned adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for Ly...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the c...
VERAXA Biotech AG appoints Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor cancer therapies, signaling a strategic pu...
NanoViricides secures $3.8 million from a registered direct offering to advance its broad-spectrum antiviral drug candidate NV-387 and other programs.
VERAXA Biotech AG has appointed Christoph Erkel as CSO to lead the development of its BiTAC platform for solid tumor cancer therapies, leveraging his ...
VERAXA Biotech has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE development, reducing uncertainty before ...
VERAXA Biotech AG announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on develo...
Siegfried's appointment of Eduardo Montanha as COO, effective September 1, 2026, supports its strategy to offer integrated end-to-end solutions across...
NextPlat Corp agrees to acquire an independent pharmacy near Pensacola, Florida, for $1.5 million to expand its PharmcoRx retail footprint into an und...
Onco-Innovations announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key step to...
VERAXA Biotech AG has initiated cell line development for its lead BiTAC T-cell engager program by partnering with ATUM, a key step toward IND/CTA-ena...
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036, fueled by rising chronic di...
VERAXA Biotech AG updated on its BiTAC platform progress, with four T-cell engager programs and two bispecific ADC programs, while seeking partnership...
VERAXA Biotech has started cell line development for its lead BiTAC T-cell engager program, aiming to improve tumor selectivity and reduce off-tumor t...
The article highlights how VERAXA Biotech AG, with its next-generation antibody platform, is poised to benefit from the sustained high level of strate...
Ace Therapeutics announces a full-spectrum preclinical analgesic drug development service with diverse in vivo pain models and integrated research cap...
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve profitability, affecting 32 employees, as ...
